Related references
Note: Only part of the references are listed.Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer
Sara Duhachek-Muggy et al.
MOLECULAR CANCER (2017)
MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1
Lin Wang et al.
ONCOTARGET (2016)
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
Tsutomu Takashima et al.
LANCET ONCOLOGY (2016)
Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes
Yan Liu et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Cks overexpression enhances chemotherapeutic efficacy by overriding DNA damage checkpoints
S. V. del Rincon et al.
ONCOGENE (2015)
Effects of 5-Fluorouracil on Morphology, Cell Cycle, Proliferation, Apoptosis, Autophagy and ROS Production in Endothelial Cells and Cardiomyocytes
Chiara Focaccetti et al.
PLOS ONE (2015)
The Disintegrin and Metalloprotease ADAM12 Is Associated with TGF-β-Induced Epithelial to Mesenchymal Transition
Michael Ruff et al.
PLOS ONE (2015)
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40-GeparQuattro)
G. von Minckwitz et al.
ANNALS OF ONCOLOGY (2014)
Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel
C. Vulsteke et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
The Effect of Disintegrin-Metalloproteinase ADAM9 in Gastric Cancer Progression
Jeong Min Kim et al.
MOLECULAR CANCER THERAPEUTICS (2014)
ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins
Camilla Frohlich et al.
BIOCHEMICAL JOURNAL (2013)
Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype
Hui Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells
Qing-ping Wang et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2013)
14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation
Guopei Zheng et al.
FEBS LETTERS (2012)
The 2011 EBCTCG polychemotherapy overview
Carlo Palmieri et al.
LANCET (2012)
Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials
Jordi Gines et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2011)
Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients with Primary Breast Cancer
Hiroji Iwata et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
ADAM12 Transmembrane and Secreted Isoforms Promote Breast Tumor Growth A DISTINCT ROLE FOR ADAM12-S PROTEIN IN TUMOR METASTASIS
Roopali Roy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through the NF-κB pathway in MCF-7 cells
Xuedong Wang et al.
FEBS LETTERS (2010)
Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis
Xavier Paoletti et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
ADAM10 Is Upregulated in Melanoma Metastasis Compared with Primary Melanoma
Sophia B. Lee et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
Vlad Popovici et al.
BREAST CANCER RESEARCH (2010)
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Pierre Farmer et al.
NATURE MEDICINE (2009)
Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways
Aisha Siddiqa et al.
BMC CANCER (2008)
The ADAMs: signalling scissors in the tumour microenvironment
Gillian Murphy
NATURE REVIEWS CANCER (2008)
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
Shinichi Sakuramoto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The disintegrin and metalloproteinase ADAM12 contributes to TGF-β signaling through interaction with the type II receptor
Azeddine Atfi et al.
JOURNAL OF CELL BIOLOGY (2007)
Proteolytic processing of Delta-like 1 by ADAM proteases
Emilia Dyczynska et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis
T Ohtsuka et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Selective modulation of integrin-mediated cell migration by distinct ADAM family members
J Huang et al.
MOLECULAR BIOLOGY OF THE CELL (2005)
Extending survival with chemotherapy in metastatic breast cancer
J O'Shaughnessy
ONCOLOGIST (2005)
ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands
M Tanaka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
PACSIN3 binds ADAM12/meltrin α and up-regulates ectodomain shedding of heparin-binding epidermal growth factor-like growth factor
S Mori et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
ADAM15 overexpression in NIH3T3 cells enhances cell-cell interactions
B Herren et al.
EXPERIMENTAL CELL RESEARCH (2001)
Share Paper
